AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$ORKA

Quinlan Paul T sold $936K of ORKA

Quinlan Paul T (General Counsel) sold 10,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $93.64 ($92.37–$95.31, $0.94M total) across 4 trades on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Quinlan Paul T
Published Sep 21, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 9:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORKA
Bearish
medium confidence
Mentioned
$ORKA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORKABearishLow
01

Why it matters

The disclosed sale is modest and likely already priced in, offering limited trading edge.

02

Market read

Provides a fresh insider‑sale data point for ORKA; minimal broader market relevance.

03

What to watch

Potential upcoming clinical data or partnership announcements could offset the negative signal.

Relevance 4/10Novelty 4/10Timing: filing date today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$ORKABearishMedium confidence
Context

General Counsel Quinlan Paul T sold 10,000 ORKA shares for $936,417 via a 10b5‑1 plan on 2026‑09‑21.

Expected impact

Potential short‑term dip of 1‑2% as market digests the sale.

Evidence & confidence

A 10b5‑1 sale by a senior officer indicates a willingness to liquidate, but the amount ($936k) is small for a mid‑cap biotech, limiting price impact.

Market effects

Sector

Minor signal for biotech sector; no broader impact.

Regional

U.S. market only; negligible regional effect.

Global

Limited to investors tracking ORKA.

Counterpoint

What could challenge this read

The sale may be routine under a pre‑arranged plan and not indicative of future weakness.

Key entities

  • company
    Oruka Therapeutics, Inc.

    Biotech firm developing therapies; ticker ORKA.

  • person
    Quinlan Paul T

    General Counsel and officer of Oruka Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORKA insider trading history →

Related articles

OCT 1
$ORKAMedAI 8/10

How Investors Are Reacting To Oruka Therapeutics (ORKA) Positive Psoriasis Trial Results

Oruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A Phase 2a trial for ORKA-001 in treating moderate-to-severe plaque psoriasis. The drug showed high PASI 90 and PASI 100 response rates, maintained IGA 0/1 responses, and had a safety profile consistent with the IL-23p19 class. The company has no revenue, reported a net loss of $109.688m, and relies on clinical trials and funding. The stock is up sharply over the past year but down 10.2% over the last month.

simplywall.st2 min
SEP 23
$ORKAMedAI 8/10

Why is Oruka Therapeutics stock sliding today?

Oruka Therapeutics' stock fell 2.5% in pre-market trading after releasing positive but expected Week 28 trial data, with 71.4% of patients achieving complete skin clearance. The company's Chief Medical Officer highlighted the potential of ORKA-001. A pre-planned insider sale of 10,000 shares and a cautious market backdrop also contributed to the decline. Oruka's Price-to-Sales ratio remains high, reflecting growth expectations. The company plans to share more data in December 2026 and Q4 2026.

investing.com2 min